A Review of Sodium Oxybate and Baclofen in the Treatment of Sleep Disorders
Studies examining GABAB receptor agonists have reported effects on sleep including decreased sleep onset latency (SOL), increased sleep consolidation and increases in slow wave sleep (SWS). γ-hydroxybutyrate (GHB) is proposed to act as a GABAB receptor agonist; however, the mechanism
of action of GHB is controversial. In addition, the GABAB receptor agonist, baclofen, has also been proposed to exert similar effects on sleep. The aim of this paper is to provide a review of the human clinical studies of sodium oxybate and baclofen regarding sleep and the treatment of sleep
disorders including narcolepsy and insomnia, as well as other disorders involving disrupted sleep such as fibromyalgia.
Keywords: -butyrolactone; Baclofen; GABA-B; GHB; Gamma Hydroxybutyrate; Insomnia; Narcolepsy; Polysomnograms; Sodium Oxybate; Xyrem; cataplexy; episodic; fibromyalgia; hyperpolarization; insomnia; narcolepsy; schizophrenia; succinic semialdehyde; triazolam
Document Type: Research Article
Publication date: 01 May 2011
- Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism. - Editorial Board
- Information for Authors
- Subscribe to this Title
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content